Every A/B testing platform eventually forces a choice: does "significant" mean a p-value crossed 0.05, or does it mean a posterior probability crossed 95%? The two frameworks often agree on which variant wins, but they answer different questions, fail differently under peeking, and require different discipline when you're comparing your results against a StatFacts insight card. Getting this wrong doesn't just confuse a debrief — it changes how much you should trust the number you're about to ship on.

Two Questions That Sound Like One

The core confusion is linguistic before it's mathematical.

  • Frequentist statistics ask: if there were truly no difference between variants, how surprising would data this extreme be? The p-value is that surprise, computed under a fixed null hypothesis, using a test statistic whose distribution is defined by imagining the experiment repeated infinitely.
  • Bayesian AB testing asks: given the data I've observed and what I believed beforehand, how probable is it that B beats A, and by how much? The output is a posterior probability — a direct statement about the hypothesis, not about hypothetical repeated sampling.

A p-value of 0.03 does not mean "97% chance B is better." That's the single most common misreading in growth teams, and it's a category error: p-values describe the data's compatibility with the null, not the probability of any hypothesis being true. A Bayesian posterior probability of 97% for "B > A" is a direct answer to the question most stakeholders actually asked in the meeting.

Where Each Framework Breaks Down in Practice

Neither approach is safe by default — each has a specific failure mode that shows up in real dashboards.

Frequentist: the peeking problem

Classical significance testing assumes you fix your sample size (or stopping rule) in advance and look once. Checking the dashboard daily and stopping the moment p < 0.05 inflates the false-positive rate far above 5% — sometimes past 20-30% depending on how often you peek. This is why StatFacts' guide on preventing p-hacking treats early stopping as a primary risk, not an edge case. Sequential correction methods (alpha-spending, always-valid p-values) fix this, but plain t-tests and chi-square tests checked repeatedly do not.

Bayesian: the prior problem

Bayesian methods handle continuous monitoring more gracefully — the posterior updates honestly as data arrives and doesn't require a pre-committed stopping rule in the same way. But the framework shifts the risk into the prior. A strongly informative prior pulling toward "no effect" will understate a real lift; a flat, uninformative prior on a low-traffic test can make noisy early results look more decisive than they are. Teams that switch to Bayesian dashboards to escape peeking penalties sometimes just relocate the same optimism into prior selection, especially when the prior is quietly set to "whatever made last quarter's test look good."

Reading the Same Effect Two Ways

Question Frequentist answer Bayesian answer
"Is this real?" p = 0.02 (reject null at α=0.05) P(B > A) = 96%
"How big is it?" Point estimate + 95% confidence interval Posterior mean + 95% credible interval
"Can I stop early?" Only with pre-specified sequential design Yes, posterior is valid at any point, given the prior is reasonable
"What if I run it again?" CI covers the true effect 95% of the time across repeated experiments Credible interval contains the true effect with 95% probability, given the model

The interval language is where teams trip most often: a 95% confidence interval is a statement about the procedure's long-run coverage, not a 95% probability that this specific interval contains the true effect. A 95% credible interval is exactly the latter. When a StatFacts insight card reports an effect range alongside a confidence label, treat the range as descriptive of typical outcomes across studies — not as either kind of interval from a single test — and don't collapse the two definitions when you cite it.

Matching the Framework to the Decision

Neither approach is universally correct; the right choice depends on what the test is for.

  • High-stakes, one-shot launches (pricing changes, checkout flow rewrites) benefit from frequentist rigor with a pre-registered stopping rule, because the cost of a false positive is high and stakeholders want a defensible, standardized threshold.
  • High-velocity iteration (headline copy, button color, onboarding microcopy) favors Bayesian monitoring, because teams need to make continuous ship/kill calls without waiting for a fixed sample size, and the cost of any single wrong call is low.
  • Low-traffic experiments (B2B, enterprise, niche segments) generally favor Bayesian methods with a modest, honestly-documented prior — frequentist tests on small samples either never reach significance or require impractically long run times.
  • Cross-team or cross-company comparisons, including checking your result against a StatFacts benchmark, are easier in frequentist terms, since most published effect sizes and sample_context fields on insight cards are reported from classical A/B tests rather than posterior distributions.

Using StatFacts Benchmarks Under Either Framework

When you pull up an insight card to sanity-check a result, the confidence label tells you what kind of evidence generated the effect range — most StatFacts A/B test entries are frequentist in origin, so an observed effect near the low end of the range with a Bayesian posterior probability just above 90% is not a contradiction; it's two lenses on modest evidence. Two habits keep both frameworks honest against benchmark data:

  1. Compare magnitude, not just the decision. A p < 0.05 result or a posterior > 95% only tells you a direction is likely. Line the point estimate or posterior mean up against the insight card's effect range to judge whether the lift is typical, unusually large, or too small to matter operationally.
  2. Check sample_context before trusting either interval. A tight frequentist confidence interval or a concentrated posterior from a test run on a narrow user segment doesn't transfer to a different product surface just because the interval looks precise. Precision and relevance are separate questions.

Practical Setup Notes

  • If your experimentation platform supports both, run Bayesian posterior tracking for internal go/no-go calls and report frequentist p-values in documents that leave the team, since external reviewers and most cited literature still default to that language.
  • Document your prior (or your significance threshold) before the test starts, in the same spirit as the pre-registration practice described in the p-hacking guide — a prior chosen after seeing early results is no more honest than a stopping rule chosen after seeing early p-values.
  • Report an interval alongside any point estimate, and always label which kind it is. "95% CI" and "95% credible interval" are not interchangeable in a deck, even though they're often typed as if they were.

Related Resources from StatFacts:

Let me know if you'd like this saved to app/content/guides/bayesian-vs-frequentist-ab-testing.md — the write attempt is pending your approval.